About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals is a company based in Watertown (United States) founded in 1987 was acquired by pSivida in March 2018. The company has 165 employees as of December 31, 2024. EyePoint Pharmaceuticals has completed 2 acquisitions, including Contractordeliverysystems and Icon Bioscience. EyePoint Pharmaceuticals offers products and services including DURAVYU™ and Durasert E™. EyePoint Pharmaceuticals operates in a competitive market with competitors including Rezolute, Molecular Partners, Aviceda Therapeutics, IVERIC bio and EyeBio, among others.
- Headquarter Watertown, United States
- Employees 165 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Eyepoint Pharmaceuticals, Inc.
-
Annual Revenue
$43.27 M (USD)-5.97as on Dec 31, 2024
-
Net Profit
-$130.87 M (USD)-84.86as on Dec 31, 2024
-
EBITDA
-$144.31 M (USD)-97.16as on Dec 31, 2024
-
Latest Funding Round
$15.7 M (USD), Post-IPO
Jan 03, 2021
-
Investors
pSivida
& 5 more
-
Employee Count
165
as on Dec 31, 2024
-
Investments & Acquisitions
Contractordeliverysystems
& 1 more
-
Acquired by
pSivida
(Mar 28, 2018)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of EyePoint Pharmaceuticals
EyePoint Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol EYPT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of EyePoint Pharmaceuticals
EyePoint Pharmaceuticals offers a comprehensive portfolio of products and services, including DURAVYU™ and Durasert E™.
Investigational treatment for VEGF mediated retinal diseases.
Proprietary system for sustained intraocular drug delivery.
Funding Insights of EyePoint Pharmaceuticals
Investors in EyePoint Pharmaceuticals
EyePoint Pharmaceuticals has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include pSivida, OcuMension and SWK Holdings.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
CRG is recognized as a premier healthcare investment partner.
|
Locked | Locked | Locked | |
|
Growth-stage healthcare companies are invested in by EW Healthcare Partners.
|
Locked | Locked | Locked | |
|
Ophthalmic drugs for eye disorders are developed.
|
Locked | Locked | Locked |
Investor details for EyePoint Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by EyePoint Pharmaceuticals
EyePoint Pharmaceuticals has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Contractordeliverysystems and Icon Bioscience.
Investment portfolio details for EyePoint Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Online pharmacy providing prescription drugs and other health products
|
Locked | Locked | 2004 | Locked | |
|
Provider of commercial construction services including concrete, painting, and tenant finish
|
Locked | Locked | 0 | Locked |
Complete acquisition details for EyePoint Pharmaceuticals
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - EyePoint Pharmaceuticals
Detailed financials for EyePoint Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Eyepoint Pharmaceuticals Comparisons
Peer comparison for EyePoint Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of EyePoint Pharmaceuticals
EyePoint Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Rezolute, Molecular Partners, Aviceda Therapeutics, IVERIC bio and EyeBio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for metabolic and orphan diseases are developed by Rezolute.
|
|
| Locked | Locked | Locked |
Therapeutic solutions for diseases are developed using DARPin technology.
|
|
| Locked | Locked | Locked |
Biotherapeutics for glycol-immune diseases are developed across multiple therapeutic areas.
|
|
| Locked | Locked | Locked |
Gene therapy solutions for retinal diseases are developed.
|
|
| Locked | Locked | Locked |
Therapies for ophthalmological diseases are developed to restore vision.
|
Detailed competitors of EyePoint Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Eyepoint Pharmaceuticals
Complete news archive for EyePoint Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about EyePoint Pharmaceuticals
EyePoint Pharmaceuticals was founded in 1987 and raised its 1st funding round 31 years after it was founded.
EyePoint Pharmaceuticals is headquartered in Watertown, United States.
As of Dec 31, 2024, the latest employee count at EyePoint Pharmaceuticals is 165.
Annual revenue of EyePoint Pharmaceuticals is $43.27M as on Dec 31, 2024.
EyePoint Pharmaceuticals was founded in 1987 and is headquartered in Watertown, United States. Operations focus on the biotechnology sector, where small molecule-based therapeutics for ophthalmic disorders are developed. A proprietary Durasert technology is employed, consisting of a miniaturized, injectable, sustained-release drug delivery system for small molecules. Lead candidates include Yutiq, targeted at chronic non-infectious uveitis, and EYEP-1901, addressed to wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion.
EyePoint Pharmaceuticals's top competitors include Rezolute, Molecular Partners and Aviceda Therapeutics.
EyePoint Pharmaceuticals offers DURAVYU™ and Durasert E™.
Yes, EyePoint Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol EYPT.
EyePoint Pharmaceuticals has made 2 acquisitions, including Contractordeliverysystems, and Icon Bioscience.
EyePoint Pharmaceuticals has 6 investors. Key investors include pSivida, OcuMension, SWK Holdings, CRG, and EW Healthcare Partners.
The ticker symbol of EyePoint Pharmaceuticals is EYPT on NASDAQ.